Company intelligence / Profile preview

Immtech Pharmaceuticals, Inc.

Vernon Hills, Illinois, United States

Ownership: Private
Employees: ~20
Development stage: Phase 3

Overview

Immtech Pharmaceuticals developed a proprietary dication-based small molecule platform with lead candidates targeting malaria, African sleeping sickness, Pneumocystis pneumonia, tuberculosis, fungal infections and resistant bacterial pathogens. Their most advanced candidate was pafuramidine maleate (DB289) for malaria and trypanosomiasis. However, all known clinical programs were ultimately discontinued due to efficacy/safety issues or strategic reasons; the company appears inactive with no current pipeline activity reported since mid-late2000s.

Therapeutic areas: Infectious Diseases
Modalities: Small moleculesRecombinant proteinsMonoclonal antibodies (in partnership/distribution context)
Industry: Biotech

Drug pipeline

1 asset

pafuramidine

Partnerships

Medicines for Malaria Venture(MMV )University of North Carolina at Chapel Hill(UNC–CH )

Beyond the preview

Go deeper on Immtech Pharmaceuticals, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Immtech Pharmaceuticals, Inc..

Explore the full profile